Home › Trials › NCT05476926

Collecting real-world data on Roche ophthalmology products

Real-World, Long-Term Data Collection to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER STUDY)

Observational Hoffmann-La Roche · NCT05476926

This study is trying to gather long-term information on how well Roche eye treatments work and how they are used by people with certain eye conditions in everyday settings.

Quick facts

Study typeObservational
Enrollment6000 (estimated)
Ages18 Years and up
SexAll
SponsorHoffmann-La Roche Industry-sponsored
Drugs / interventionsFaricimab, Ranibizumab
Locations242 sites (Phoenix, Arizona and 241 other locations)
Trial IDNCT05476926 on ClinicalTrials.gov

What this trial studies

The VOYAGER study is a non-interventional, prospective, multinational study aimed at gathering long-term data on the effectiveness and safety of Roche ophthalmology products for conditions like neovascular age-related macular degeneration and diabetic macular edema. It focuses on understanding treatment patterns and the factors influencing treatment decisions among patients receiving these therapies in routine clinical practice. The study does not influence standard care and is designed to provide insights based on real-world usage of the products.

Who should consider this trial

Good fit: Ideal candidates include adult patients newly initiating or continuing treatment with specified Roche ophthalmology products for retinal conditions.

Not a fit: Patients currently participating in other investigational ophthalmology clinical trials may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of treatment effectiveness and safety for patients with retinal conditions.

How similar studies have performed: Other studies have shown success in collecting real-world data for similar ophthalmology products, indicating the potential for valuable insights.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Have provided informed consent, as required per local regulations 2.a) Adult patient, as defined by local regulations and local product label, who is newly initiating treatment (or initiated treatment in the previous visit) with a specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye, according to the investigator's discretion in routine clinical practice; OR 2.b) Adult patient, as defined by local regulations and local product label, who is continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye after initiating that treatment in a Roche interventional trial.

Exclusion Criteria:

1. Concomitant participation of the patient in an investigational ophthalmology clinical trial that includes receipt of any investigational drug or procedure within the last 28 days prior to enrollment (this restriction does not apply to patients who are rolling over from Roche interventional studies and continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study)

Where this trial is running

Phoenix, Arizona and 241 other locations

+192 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein OcclusionBranch Retinal Vein OcclusionCentral Retinal Vein OcclusionHemi-retinal Vein Occlusion
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.